BioElectron Update

Print Friendly, PDF & Email

Guy Miller, BioElectron’s CEO, and Matthew Klein, its Chief Medical Officer, will discuss the following:

  • Challenges in the development of drugs for mitochondrial disease
  • Status of BioElectron mitochondrial disease programs
  • Next steps
About The Speaker:

Guy Miller, MD, PhD is Founder, Chairman, and Chief Executive Officer of BioElectron Technology Corporation. BioElectron is a technology company focused on biological energy. Dr. Miller holds a PhD in chemistry and an MD, with subspecialty training in critical care medicine. He completed his surgical internship at University of Chicago, and completed his residency and fellowship training at Johns Hopkins, where he was an assistant professor. His research has been funded by numerous organizations including DARPA. He is an attending physician in medical surgical critical care at Stanford University Medical Center/VAPAHCS.

Matthew B. Klein, MD, MS, FACS is Chief Medical Officer of BioElectro Technology Corporation. He received his MD degree from Yale University and completed his surgical training at Stanford University. He also holds a Master’s degree in Epidemiology. Dr. Klein most recently held the David and Nancy Auth-Washington Research Foundation Endowed Chair for Restorative Burn Surgery at the University of Washington where he was a professor of surgery and epidemiology. His clinical and research expertise spans several fields, including skin biology, wound healing, systemic inflammatory disorders, clinical trials, and nutrition. Dr. Klein has authored or co-authored over 80 peer-reviewed manuscripts and 15 book chapters related to these areas, and sits on the editorial review boards of several prominent biomedical journals. He is currently a clinical associate professor at Stanford University.

Date: 06/23/2017
Speaker: Guy Miller & Matthew Klein
PDF: Click Here
Listen Now: Click Here
View Slides: Click Here

Related Articles

Stealth BioTherapeutics MMPOWER Update
Speaker: Reenie McCarthy
Drug Trial Begins Targeting Mitochondrial Diseases
Date: 07/15/2008
Speaker: Dr. Guy Miller